drugset / Trial / NCT03356080
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with blast excess
Timeline
- Start
- 2017-07-07
- Primary completion
- 2019-07-07
- Completion
- 2020-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Decitabine | Small molecule | 0.1 mg/kg | Intravenous |
| Subject | Decitabine | Small molecule | 0.2 mg/kg | Intravenous |
| Subject | Tretinoin | Small molecule | 15 mg | — |
| Background | G-CSF | Unknown | 300 ug | Subcutaneous |